Publication:
Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease.

dc.contributor.authorChaparro, M
dc.contributor.authorGarre, A
dc.contributor.authorGuerra Veloz, M F
dc.contributor.authorVázquez Morón, J M
dc.contributor.authorDe Castro, M L
dc.contributor.authorLeo, E
dc.contributor.authorRodriguez, E
dc.contributor.authorCarbajo, A Y
dc.contributor.authorRiestra, S
dc.contributor.authorJiménez, I
dc.contributor.authorCalvet, X
dc.contributor.authorBujanda, L
dc.contributor.authorRivero, M
dc.contributor.authorGomollón, F
dc.contributor.authorBenítez, J M
dc.contributor.authorBermejo, F
dc.contributor.authorAlcaide, N
dc.contributor.authorGutiérrez, A
dc.contributor.authorMañosa, M
dc.contributor.authorIborra, M
dc.contributor.authorLorente, R
dc.contributor.authorRojas-Feria, M
dc.contributor.authorBarreiro-de Acosta, M
dc.contributor.authorKolle, L
dc.contributor.authorVan Domselaar, M
dc.contributor.authorAmo, V
dc.contributor.authorArgüelles, F
dc.contributor.authorRamírez, E
dc.contributor.authorMorell, A
dc.contributor.authorBernardo, D
dc.contributor.authorGisbert, J P
dc.date.accessioned2023-01-25T13:32:37Z
dc.date.available2023-01-25T13:32:37Z
dc.date.issued2019
dc.description.abstractTo evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 in comparison with patients who maintain Remicade®. Patients under Remicade® who were in clinical remission with standard dosage at study entry were included. The 'switch cohort' [SC] comprised patients who made the switch from Remicade® to CT-P13, and the 'non-switch' cohort [NC] patients remained under Remicade®. A total of 476 patients were included: 199 [42%] in the SC and 277 [58%] in the NC. The median follow-up was 18 months in the SC and 23 months in the NC [p Switching from Remicade® to CT-P13 might be associated with a higher risk of clinical relapse, although this fact was not supported in our study by an increase in objective markers of inflammation. The nocebo effect might have influenced this result. Switching from Remicade® to CT-P13 was safe.
dc.identifier.doi10.1093/ecco-jcc/jjz070
dc.identifier.essn1876-4479
dc.identifier.pmid30976785
dc.identifier.unpaywallURLhttps://zaguan.unizar.es/record/88399/files/texto_completo.pdf
dc.identifier.urihttp://hdl.handle.net/10668/13818
dc.issue.number11
dc.journal.titleJournal of Crohn's & colitis
dc.journal.titleabbreviationJ Crohns Colitis
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Juan Ramón Jiménez
dc.organizationHospital Universitario Regional de Málaga
dc.organizationÁrea de Gestión Sanitaria Sur de Sevilla
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.organizationAGS - Sur de Sevilla
dc.page.number1380-1386
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.rights.accessRightsopen access
dc.subjectCrohn’s disease
dc.subjectInflammatory bowel disease
dc.subjectRemicade®
dc.subjectsup > CT-P13
dc.subjectswitch
dc.subjectulcerative colitis
dc.subject.meshAdult
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshCohort Studies
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshGastrointestinal Agents
dc.subject.meshHumans
dc.subject.meshInflammatory Bowel Diseases
dc.subject.meshInfliximab
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshRecurrence
dc.subject.meshRetrospective Studies
dc.titleEffectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease.
dc.typeresearch article
dc.type.hasVersionAM
dc.volume.number13
dspace.entity.typePublication
Files